implant probuphine dispenses low dose buprenorphine six month period proponent hope would reduce chance abusethe food drug administration approved first implantable opioid addiction treatment thursday decision come obama administration work respond america opioid addiction epidemic 80 american die day overdoses deadly crisis mapping spread america drug overdose epidemic read opioid abuse addiction taken devastating toll american family we must everything make new innovative treatment option available help patient regain control life said fda commissioner robert califf statement implant probuphine continuously dispenses low dose anti addiction drug buprenorphine six month period it intended patient already shown stable low dos buprenorphine common treatment opioid addiction previously available dissolvable film tablet one handful medication approved treatment opioid dependence the two methadone naltrexone latter combined buprenorphine opioid addiction drug fda advisory committee voted 12 5 favor approving implant january proponent implant hoped would reduce chance drug consumed child resold abused voted drug approval expressed concern science used prove implant safe training doctor would need implant drug some also said concerned committee approving drug desperation treatment option address crisis fda announce whether approve implant opioid addict read morethe drug manufactured braeburn pharmaceutical whose president ceo behshad sheldon said statement company hope first hope many new treatment addiction opioid addiction chronic disease treated way treat serious chronic disease evidence based medicine sheldon said wholesale cost probuphine 825 per month yet clear much implant cost doctor patient buprenorphine approved tablet 2002 addiction specialist called increased access drug specially trained doctor prescribe 100 patient sheldon told guardian week braeburn campaigning lawmaker make probuphine exception cap doctor prescribe medication must trained surgically insert remove four one inch long set rod sheldon said previously drug approved braeburn would hold 253 session train 3 000 doctor first six week approval